

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-71. (Canceled)

72. (Newly added) A purified polypeptide comprising the amino acid sequence Cys Cys Glu Xaa Cys Cys Asn Pro Ala Cys Thr Gly Cys wherein Xaa is selected from Phe, Trp and Tyr (SEQ ID NO: 125).

73. (Newly added) The purified polypeptide of claim 72 wherein the polypeptide consists essentially of the amino acid sequence Cys Cys Glu Xaa Cys Cys Asn Pro Ala Cys Thr Gly Cys wherein Xaa is selected from Phe, Trp and Tyr (SEQ ID NO: 125).

74. (Newly added) A purified polypeptide consisting of the amino acid sequence Cys Cys Glu Xaa Cys Cys Asn Pro Ala Cys Thr Gly Cys wherein Xaa is selected from Phe, Trp and Tyr (SEQ ID NO: 125).

75. (Newly added) The purified polypeptide of claim 72 wherein the polypeptide comprises the amino acid sequence Cys Cys Glu Xaa Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr wherein Xaa is selected from Phe, Trp and Tyr (SEQ ID NO:126).

76. (Newly added) The purified polypeptide of claim 72 wherein the polypeptide consists essentially of the amino acid sequence Cys Cys Glu Xaa Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr wherein Xaa is selected from Phe, Trp and Tyr (SEQ ID NO:126).

77. (Newly added) The purified polypeptide of claim 72 comprising the amino acid sequence Cys Cys Glu Xaa Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr wherein Xaa is selected from Phe, Trp and Tyr (SEQ ID NO:126).

78. (Newly added) A pharmaceutical composition comprising the purified polypeptide of claim 72.

79. (Newly added) A method for treating a gastrointestinal disorder in patient, the method comprising administering to the patient a composition comprising the purified polypeptide of claim 72.

80. (Newly added) The method of claim 79 wherein the gastrointestinal disorder is selected from the group consisting of a gastrointestinal motility disorder, post operative ileus, opiate induced constipation irritable bowel syndrome, chronic constipation, a functional gastrointestinal disorder, gastroesophageal reflux disease, functional heartburn, dyspepsia, functional dyspepsia, nonulcer dyspepsia, gastroparesis, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, ulcerative colitis, and inflammatory bowel disease.

81. (Newly added) The method of claim 79 wherein the composition is administered orally.

82. (Newly added) The method of claim 79 wherein the purified peptide is administered rectally.

83. (Newly added) The method of claim 79 wherein the purified peptide is administered parenterally.

84. (Newly added) The pharmaceutical composition of claim 78 further comprising an analgesic compound.

85. (Newly added) A method for activating GC-C receptors in the intestine of a patient, the method comprising administering to the patient a composition comprising the purified polypeptide of claim 72.

86. (Newly added) The method of claim 86 wherein the composition is administered orally.

87. (Newly added) The method of claim 86 wherein the composition is administered rectally.

88. (Newly added) The method of claim 86 wherein the composition is administered parenterally.

89. (Newly added) A method for treating visceral pain in a patient, the method comprising administering a composition comprising the purified polypeptide of claim 72.